Neurophysiologic Biomarkers in Neuropsychiatric Disorders : Etiologic and Treatment Considerations / edited by Daniel C. Javitt, James C. McPartland.

Format:

Book

Author/Creator:

Javitt, Daniel C.

Contributor:

McPartland, James C.

Series:

Advances in Neurobiology, 2190-5223 ; 40

Language:

English

Subjects (All):

Psychiatry.

Neurosciences.

Neurology.

Pharmacology.

Neuroscience.

Local Subjects:

Psychiatry.

Neuroscience.

Neurology.

Pharmacology.

Physical Description:

1 online resource (832 pages)

Edition:

1st ed. 2024.

Place of Publication:

Cham : Springer Nature Switzerland : Imprint: Springer, 2024.

Summary:

This book reviews neurophysiological biomarkers in neuropsychiatric disorders from the viewpoint of the 21st Century Cures Act, which encourages the use of biomarkers for a variety of purposes during drug development. It covers both traditional etiologic uses of biomarkers and the more recent Biomarkers, EndpointS, and other Tools (BEST) classification scheme used by the FDA, which permits biomarkers for purposes of susceptibility, diagnosis, monitoring, prognosis, pharmacodynamics/response, and safety. The first section of the book describes potential uses of neurophysiologic biomarkers. Subsequent sections focus on a wide range of conditions, including schizophrenia, autism spectrum disorder, Parkinson’s disease, and depression, as well as cross-diagnostic and translational uses, including monkey and rodent analogs. The purpose of the book is to help clinicians understand how neurophysiological biomarkers may be used to understand and manage clinical conditions; to help researchers to understand how biomarkers may be used translationally to test specific theories; and to help pharma investigators to understand how biomarkers can be used to accelerate treatment development.

Contents:

Introduction to volume: Biomarkers in Psychiatry

Part I: Government and Pharma perspectives on biomarker development

Biomarker Methodologies: a NIMH Perspective

Neural Circuitry-related biomarkers for drug development in psychiatry – An industry perspective

Public Private Partnerships for Neuropsychiatric Drug Development: A Perspective

Part II: Biomarker methodologies and Translational Approaches

Methods for and use of functional magnetic resonance imaging in psychiatry

Advanced methodology for neurophysiological analysis and biomarker development: time-frequency and source-localization approaches

Magnetoencephalography in Psychiatry: A Perspective on Translational Research and Applications

Modern methods for unraveling cell- and circuit-level mechanisms of neurophysiological biomarkers in psychiatry

Rodent models for ASD biomarker development

Auditory biomarkers of neuropsychiatric disorders in nonhuman primates

Part III: Biomarkers in schizophrenia and clinical high risk

Functional Connectivity Biomarkers in Schizophrenia

The use of event-related potentials in the study of schizophrenia: An overview

Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here?

Altered sleep oscillations as neurophysiological biomarkers of schizophrenia

Neurophysiological models in individuals at clinical high risk for psychosis: Using translational EEG paradigms to forecast psychosis risk and resilience

Mismatch negativity (MMN) as a pharmacodynamic/response biomarker for NMDA receptor- and excitatory/inhibitory imbalance-targeted treatments in schizophrenia

Part IV: Biomarkers in ASD

Towards Biomarkers for Autism Spectrum Disorder: Contributions of Magnetoencephalography (MEG)

Structural Brain Imaging Biomarkers of Autism Spectrum Disorder

Delineating a pathway for the discovery of functional connectome biomarkers of autism

EEG Biomarkers for Autism : Rational, Support, and the Qualification Process

Part V: Other disorders

Translating decades of neuroscience research into diagnostic and treatment biomarkers for ADHD

Neuroimaging Biomarkers in Parkinson’s Disease

Biomarkers of Auditory-Verbal Hallucinations

Part VI: Cross-diagnostic methodologies

Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes

Biomarkers for cognitive control, response inhibition, aggressivity, impulsivity and violence

Visual neurophysiological biomarkers for patient stratification and treatment development across neuropsychiatric disorders

The less things change, the more they remain the same: Impaired neural plasticity as a critical target for drug development in neuropsychiatry.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

9783031694912

OCLC:

1472981332